Department of Clinical Immunology, National Research Center for Radiation Medicine, Academy of Medical Sciences of Ukraine, 119/121 Prospect Peremohy Str., 03115, Kyiv, Ukraine.
Department of Oncohematology, National Cancer Institute, 33/43 Lomonosova Str., 03022, Kyiv, Ukraine.
Leuk Res. 2021 Nov;110:106686. doi: 10.1016/j.leukres.2021.106686. Epub 2021 Aug 25.
The mutational status of the variable region of the immunoglobulin heavy chain (IGHV) genes remains the most significant prognostic factor in chronic lymphocytic leukemia (CLL) patients. However, the groups of mutated (M) and unmutated (UM) patients are also heterogeneous, and additional markers are used for a more accurate prognosis. The aim of our work was to determine the prognostic value of the signs of antigen selection determined by BASELINe statistics in M IGHV sequences of CLL patients. Clinical data, IGHV gene configuration, TP53, NOTCH1, SF3B1 mutations were analyzed in 127 CLL patients with M IGHV sequences. The median OS of patients with negative selection in the framework regions (FWRs) of IGHV genes was 120 months compared to 202 month in other CLL patients (P = 0.016). In multivariate Cox regression analysis Binet stage C vs A + B (P < 0.0001), SF3B1 mutations (P < 0.0001), negative selection in the FWRs (HR P = 0.007), and age ≥65 years (P = 0.034) were powerful adverse prognostic factors for OS in CLL patients with M IGHV genes. These preliminary data suggest that the signs of antigen-driven selection may be used as a prognostic factor in CLL patients with M IGHV genes in combination with other markers.
免疫球蛋白重链(IGHV)基因可变区的突变状态仍然是慢性淋巴细胞白血病(CLL)患者最重要的预后因素。然而,突变(M)和未突变(UM)患者群体也存在异质性,需要使用其他标志物进行更准确的预后。我们的工作旨在确定 BASELINe 统计确定的抗原选择迹象在 M IGHV 序列 CLL 患者中的预后价值。分析了 127 例 M IGHV 序列 CLL 患者的临床数据、IGHV 基因构型、TP53、NOTCH1、SF3B1 突变。IGHV 基因框架区(FWRs)存在负选择的患者中位 OS 为 120 个月,而其他 CLL 患者为 202 个月(P=0.016)。在多变量 Cox 回归分析中,Binet 分期 C 与 A+B(P<0.0001)、SF3B1 突变(P<0.0001)、FWRs 负选择(HR P=0.007)和年龄≥65 岁(P=0.034)是 M IGHV 基因 CLL 患者 OS 的不良预后因素。这些初步数据表明,抗原驱动选择的迹象可以与其他标志物结合,作为 M IGHV 基因 CLL 患者的预后因素。